Auto-antibodies against intracellular components can be found in cancer patients (Imai et al., 1992; Nelson, 1977; Schattner et al., 1983; Tan, 1991; Wasserman et al., 1975) . For example, auto-antibodies to p53 and cyclin B1 have been reported in certain malignancies (Winter et al., 1992; Covini et al., 1997) . Development of antibodies against p53 appears to be dependent on p53 mutations (Winter et al., 1992) . Missense mutations of p53 gene result in increased stability, prolong the half-life of the p53 and the resistance to degradation gives rise to the immune response. In the case of auto-antibodies against cyclin B1, dysregulation of cyclins may result in such proteins stimulating autoantibody responses (Covini et al., 1997) .
Telomerase, multi-subunit specific reverse transcriptase, maintains the ends of eukaryotic chromosomes, termed telomeres. Without a new synthesis of telomeres at chromosome ends the chromosomes shorten with progressive cell division, eventually triggering either replicative senescence or apoptosis when telomere length becomes critically short. The catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), is the rate-limiting factor of enzyme telomerase. Ectopic expression of hTERT is sufficient to restore telomerase activity in cells that lack the enzyme and can immortalize many cell types (Bodnar et al., 1998) . Telomerase is tightly repressed in the vast majority of normal human somatic cells but becomes activated during cellular immortalization and in cancers (Shay and Wright, 1996; Kim et al., 1994) . The ectopic expression of hTERT with two oncogenes, Ras and SV40 large T antigen, results in the direct tumorigenic conversion of several types of normal human epithelial cells (Hahn et al., 1999; Elenbaas et al., 2001) , indicating that hTERT plays an important role in the process of malignant transformation. While the mechanisms for telomerase activation in cancers have not been fully defined, they include telomerase catalytic subunit gene (hTERT) amplification. In humans, telomerase confers immortality upon incipient cancer cells, and telomerase activity is required for the continued cancer growth. Thus hTERT is one of the important proteins involving in the cellular malignant transformation (Hahn et al., 1999; Elenbaas et al., 2001 ) and might be a potential auto-antigen to induce the auto-antibodies.
Recently we succeeded in producing a recombinant catalytic subunit of telomerase, hTERT, in insect cells (Masutomi et al., 2000) . This recombinant hTERT is functional and active biochemically. In this study, we attempted to detect the auto-antibodies against hTERT in cancer patients' sera using this unique reagent.
We used recombinant purified hTERT as the antigen to detect auto-antibodies against hTERT in cancer patients' sera (Masutomi et al., 2000) (Figure 1a ). At first, we set out to detect the insect expressed protein by Western blotting analysis with patients' sera. Fractions from several purification steps of cFLAGhTERT (S1 and S2 fractions) were reacted with patients' sera and negative controls (Figure 1b) . We examined the same fractions by Western blotting using anti-FLAG M2 monoclonal antibody as a positive control (Figure 1b panel B) . The reaction with patient's serum and fraction from purification steps of approximately 127 kDa was specific, whereas specific signals were undetectable in serum from healthy volunteers (Figure 1b panels C and D) . We then screened the sera from patients and healthy volunteers by Western blotting with recombinant, purified hTERT as an antigen. The antigen was detected in serum samples from patients with HCC and from patients with colon cancer, stomach cancer and lung cancer but not in patients with liver cirrhosis, chronic hepatitis and normal healthy volunteers (Figure 2a and data not shown). The specific antibodies in the patient's sera were absorbed with purified hTERT (Figure 2b ), indicating that the signals detected by Western blotting in serum from cancer patients were specific. These results indicate the presence of circulating anti-hTERT antibodies in the cancer patients' sera. These autoantibodies are specific in cancer patients since we could not find the reaction in the normal sera and the specific antibodies in the cancer patients' sera were absorbed with the purified hTERT. Western blotting showed that the signals were diminished in serum samples by this procedure.
Next we set up the enzyme linked immunosorbent assay (ELISA) to screen the sera and statistical analyses. Since the optical density increased dosedependently according to the concentrations of the anti-M2 and anti-mouse IgG antibodies, reactions between the antigen and the M2 antibody were specific (data not shown). The mean optical densities (OD) of serum samples from 30 patients with HCC, 16 with liver cirrhosis, seven with chronic hepatitis, 18 normal healthy volunteers, and 12 patients with other types of cancer were 0.365+0.021, 0.325+0.019, 0.256+0.020, 0.239+0.013 and 0.319+0.027, respectively ( Figure 3) . The difference of O.D.s between HCC patients' sera and normal sera, and other malignancies and normal sera was statistically significant (P50.0001 and P50.01 respectively) ( Figure 3 ). Moreover, we noted that the concentration of auto-antibodies to hTERT increased as the disease progressed in chronic liver disease ( Figure 3 ). In contrast, we could not find antibodies in patients' and normal sera to bovine serum albumin (BSA) to be an irrelevant protein (data not shown). The result that we also could not find antibodies in sera to an irrelevant protein just proves to specificity of the reaction.
In a number of malignant tumors such as hepatocellular carcinoma, colon carcinoma, cervical carcinoma or certain leukemia, the progression of disease has been reported to clearly correlate with the extent of telomerase activity (Nakayama et al., 1998; Kojima et al., 1997; Nouso et al., 1996; Kitamoto and Ide, 1999; Kolquist et al., 1998) . Therefore, it would be important to investigate whether the progression of a malignant disease correlates with the amount of hTERT auto-antibodies. The results of the present a b Figure 1 (a) Purified C terminal FLAG tagged hTERT used as an antigen. We purified the recombinant hTERT according to the protocol as we previously reported (Arai et al., 2002; Masutomi et al., 2000) . Purified C terminal FLAG tagged hTERT (cFLAG-hTERT) was fractionated by 8% SDS -PAGE and stained with Coomassie brilliant blue (CBB) (lane 1). Western blotting was performed by the standard method with anti-FLAG M2 monoclonal antibody (Sigma Co. Ltd.) (lane 2) (Masutomi et al., 2000) . The predicted molecular weight of cFLAG-hTERT is about 127 kDa. Arrow indicates cFLAG-hTERT. (b) Fractions of cFLAG-hTERT protein during the purification procedures. S1 and S2 fractions of High5 cells infected with baculovirus were fractionated (Masutomi et al., 2000) . Fractions stained with Coomassie Brilliant Blue (CBB) (A). Same samples were Western blotted against anti-FLAG M2 antibody (B), against serum from a cancer patient serum treated with non-infected High5 cell lysate to absorb nonspecific antibodies (C), and against serum from a healthy volunteer (D), respectively. We obtained the sera from a total of 65 patients (age range, 40 -82 years) including 30 patients with hepatocellular carcinoma (HCC), 16 patients with liver cirrhosis (LC), seven patients with chromic hepatitis (CH), 12 patients with other malignancies. As a negative control, we obtained the sera from 18 normal healthy volunteers. These patients gave written informed consent for blood sampling. No significant differences in age and sex were found between the two groups. Proteins transferred onto nitrocellulose membranes were reacted with patient's serum diluted 50 times with TBST buffer (Tris-HCl, pH 7.4, 150 mM NaCl, 1% Tween 20) and anti-human horseradish peroxidase linked whole IgG (Amersham) was diluted 10 000-fold with TBST buffer. Lanes 1, 3, 5 and 7: S1 soluble fraction with buffer A (20 mM Tris-HCl, pH 7.5, 20% glycerol, 0.1% Nonidet P-40, 150 mM NaCl, 10 mM b-mercaptoethanol). Lanes 2, 4, 6 and 8: S2 soluble fraction with buffer B (20 mM Tris-HCl, pH 7.5, 50% glycerol, 0.5% MEGA-9, 300 mM NaCl, 10 mM b-mercaptoethanol). Arrow indicates cFLAG-hTERT Detection of auto-antibodies to hTERT K Masutomi et al study indicate that auto-antibodies in the serum of some patients with HCC are directed against antigens with functional properties associated with malignant transformation. The difference of optical density (OD) between the patients with HCC and patients with CH was significant. Since the amount of positive telomerase activity increased during hepatocarcinogenesis, we concluded that the significantly increased levels of antihTERT were due to the hTERT expression level (Nakayama et al., 1998; Kojima et al., 1997; Nouso et al., 1996) . On the other hand, although the OD of anti-hTERT antibodies in patients with LC tended to be lower than that of patients with HCC, the difference was not significant. A previous study, did not detect telomerase activity in most patients with LC or CH, but did identify the activity in several patients without cancer (12.5 -42.1%) (Nouso et al., 1996; Kitamoto and Ide, 1999) . Conceivably, some regenerative precancerous hepatic nodules or some populations of clonally expanded cells already had telomerase activity even at the LC stage, and this could have induced the immune responses against hTERT. Patients with LC who are anti-hTERT positive may quickly develop HCC, since some clones with early telomerase activity and have high potential to undergo malignant transformation combined with other genetic events.
For one individual who eventually developed HCC, we obtained serum samples and stored at successive office visits. Changes in anti-hTERT auto-antibodies during progression from the non-cancerous to the A total of 83 non-treated sera from patients and healthy volunteers were Western blotted. Only typical results are shown. Lanes 1 -3, sera from patients with cancer (H, C and G indicate HCC, colon and gastric cancer, respectively). Lanes 4 and 5, sera from patients with chronic liver disease (LC and CH indicate liver cirrhosis and chronic hepatitis, respectively). Lane 6, sera from healthy volunteers (N indicates sera from normal healthy volunteers). (b) Western blots with non-treated serum and absorbed serum. Lane 1, Western blotting by nontreated cancer patient serum; Lane 2, Western blotting by serum incubated with purified hTERT to absorb anti-hTERT auto-antibodies before blotting. In order to absorb patient's sera with purified protein, patient sera (100 ml) was added to 35 mg of purified hTERT and incubated at room temperature for 2 h, then centrifuged at 10 000 g for 10 min. The supernatant was diluted 1 : 50 with TBST buffer and Western blotted Figure 3 Comparison of optical density (OD) measured by ELISA. Wells of 96-well plates (Nunc) coated with 0.2 mg of C-terminal FLAG tagged hTERT were incubated overnight at 48C. The residual binding capacity of the plate was blocked with 100 ml of blocking buffer (9.6 mM PBS, pH 7.3, 1% BSA) (PBSB buffer) for 1 h at 378C. To measure the OD of the reaction, 100 ml of patient's serum diluted 1 : 100 with PBSB buffer was added to each well and incubated for 1 h at 378C. After five washes with PBST buffer, 100 ml of anti-human Ig (horseradish peroxidase linked whole antibody) diluted 1 : 2000 dilution with PBSB buffer was added to the wells. ABTS substrate was added and the OD was measured using a microtiter plate reader with a 405 nm filter according to the manufacturer's instructions (Nakalai). Comparison of OD measured by ELISA in sera from patients with hepatocellular carcinoma (HCC), liver cirrhosis (LC), chronic hepatitis (CH), normal control (normal) and other types of cancer is shown. A total of 12 patients with other types of cancer are seven of gastric cancer, two of lung cancer, one of pancreatic cancer, and two of colon cancer. All data are expressed as means+standard error of the mean (s.e.m.). Results were statistically analysed using Student's t-test and the w 2 test
Detection of auto-antibodies to hTERT K Masutomi et al cancerous stage of the patient were detected ( Figure  4a ). We find that a faint band was detected in the patient during the LC stage. The hTERT signal increased after this patient developed HCC. We confirmed with anti-FLAG M2 antibody that the same amount of protein was loaded in each lane (Figure 4b ). The specific signal could be recognized clearly at the first time when the patient was diagnosed as HCC. This result was confirmed by ELISA, demonstrating a significant increase in auto-antibodies against hTERT (Figure 4c ). Furthermore, a patient with stomach cancer and a patient with lung cancer were tested positive for anti-hTERT, and their sera before discovery of malignancy (before 2 years, and 1 year before cancer appearance, respectively) were analysed. Both sera were negative for anti-hTERT antibodies during the period of no malignancies (data not shown). These results suggest that at least in some patients, a novel immune response to hTERT is driven by the process of malignant transformation, and that specific circulating anti-hTERT auto-antibodies are produced. Auto-antibodies directed against intracellular antigens located in either nuclear or cytoplasm have been identified in patients with cancer. The prevalence of antinuclear antibodies was significantly increased in hepatocellular carcinoma (HCC) compared with precancerous conditions such as cirrhosis or chronic hepatitis (31 vs 13%) indicating that a novel immune response to some cellular antigens develops during malignant transformation (Imai et al., 1992; 1993a,b) . HCC was preceded by or coincided with seroconversion from antibody negative to positive status, suggesting that the novel immune responses are driven by proteins involved in the transformation process. During malignant transformation of normal cells, many proteins might be over-expressed and involved in the cellular immortalization. Such newly upregulated proteins might drive the novel immune response as auto-antigens. Many of these auto-antigens are intracellular components, involved in important cell functions (Tan, 1991) . Recent evidence suggests that the induction of auto-antibodies against such intracellular components may be relevant to the cancer.
Our results are the first so far reporting that antihTERT auto-antibodies could be detected with recombinant hTERT, and that anti-hTERT autoantibodies in sera are elevated during progression of malignancy. Since the detection of telomerase activity has generated considerable interest as a diagnostic tool, the observation of hTERT autoantibodies in the sera derived from cancer patients suggests that such autoantibodies constitute novel and specific tumor markers as a possible impact diagnostic tool (Hiyama and Hiyama, 2002) . In this sense, these results strongly suggest that serum anti-hTERT auto-antibodies would become a possible novel early tumor marker in hepatocellular carcinoma. Furthermore, since several groups have initiated vaccination strategies to induce anti-hTERT immunity, these studies suggest that cancer patients may well have on-going humoral immune responses to hTERT (Saeboe-Larssen et al., 2002; Treon et al., 2000; Vonderheide et al., 2001; Vonderheide, 2002) .
Although the basic mechanisms underlying induction of anti-hTERT auto-antibodies during malignant transformation are unknown at this point, the overexpression of hTERT in the cancer tissues might be involved in the stimulation of novel immune response. Another possibility is that auxiliary factors of telomerase, such as hsp90, p23 and/or hsp70, which are activated during process of malignancy, may positively modulate immunogenicity of hTERT by changing subcellular localization and/or degradation process of hTERT.
Further studies are necessary to clarify the molecular mechanism of induction of the auto-antibodies and to apply this potential novel tumor marker, anti-hTERT antibody, for clinically diagnostic applications. 
